This article was corrected | View correction
The release of information reporting payments made by the Medicare program to individual physicians in 2012 revealed that ophthalmologists accounted for a substantial proportion of physicians who received payments exceeding $1 million.1 A major factor contributing to these high payments for some physicians was reimbursement for treatment of age-related macular degeneration (AMD) using intravitreal injections of ranibizumab, an anti–vascular endothelial growth factor (VEGF). These drugs used for treatment of AMD are controversial not only because of their expense and the substantial payments made to some physicians who administer these drugs, but also because some anti-VEGF agents are sold at markedly different prices to different customers, representing a form of price discrimination.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.